Journal of
Marketing Development and Competitiveness






Scholar Gateway


Abstracts prior to volume 5(1) have been archived!

Issue 5(1), October 2010 -- Paper Abstracts
Girard  (p. 9-22)
Cooper (p. 23-32)
Kunz-Osborne (p. 33-41)
Coulmas-Law (p.42-46)
Stasio (p. 47-56)
Albert-Valette-Florence (p.57-63)
Zhang-Rauch (p. 64-70)
Alam-Yasin (p. 71-78)
Mattare-Monahan-Shah (p. 79-94)
Nonis-Hudson-Hunt (p. 95-106) 



JOURNAL OF LEADERSHIP, ACCOUNTABILITY AND ETHICS


Ethical Perspective: Ethics in the Pharmaceutical Industry: Vioxx Recall


Author(s): Robert Cote

Citation: Robert Cote, (2021) "Ethical Perspective: Ethics in the Pharmaceutical Industry: Vioxx Recall," Journal of Leadership, Accountability and Ethics, Vol. 18, Iss. 1, pp 11-22

Article Type: Research paper

Publisher: North American Business Press

Abstract:

The context of this paper examines the industry pressures, that led to the Vioxx Recall in 2004. Current information on the pharmaceutical industry, Federal Legislation and FDA has been updated to provide an ethical perspective comparing the past and present landscape of the industry. During the early 2000’s, the pharmaceutical industry is going through difficult times due to the external pressures from society. Some of the factors that have created industry pressures are (1) high cost of pharmaceuticals, (2) medications aren’t regulated close enough ensuring they are safe and effective, and (3) consumers lack confidence in pharmaceutical companies, Congress, and governmental agencies. As a result, Congress, pharmaceutical companies, and governmental agencies need to work together as a team to rebuild the confidence of consumers by implementing ethical processes that will drive the pharmaceutical industry in the right direction. By developing, implementing, and evaluation processes to overcome these factors, the pharmaceutical industry can ensure they are doing the right ethical measures to meet the needs of society.